

CME Symposium
IN ASSOCIATION WITH THE
FREE LIVE INTERACTIVE ONLINE

18th
WCIRDC

EARN
CME
ABIM-MOC
CREDITS
2.00

Heart Failure and Kidney Disease: The Next Epidemics

Thursday, December 3, 2020
1:15 PM – 3:10 PM
Pacific Standard Time
Los Angeles, CA

All content available ON-DEMAND
for 90 DAYS following the meeting

This is a CME Symposium Supported by an Educational Grant from **AstraZeneca**
Free for all 18th WCIRDC Attendees | Register Online: wcir.org/registration

Provided By:



Administered By:





Heart Failure and Kidney Disease: The Next Epidemics

CHAIR: Yehuda Handelsman, MD

1:15 PM	Introduction Yehuda Handelsman, MD, Chair
1:20 PM	Epidemiology and Traditional Management of HF and CKD Maria Rosa Costanzo, MD
1:40 PM	The Future Is Here: Contemporary Approach to HF with a Focus on HFrEF Mikhail Kosiborod, MD
2:00 PM	Revolution in the Management of Moderate to Severe CKD Katherine Tuttle, MD
2:20 PM	Impact of Recent CVOTs on Contemporary Guidelines for HF and CKD Muthiah Vaduganathan, MD
2:40 PM–3:10 PM	Panel Discussion and Q&A: The Cardiorenal Syndrome — Is It More Than the Sum of the Individual Components? Moderator: Peter McCullough, MD, PhD

Program Description

Heart failure (HF) and chronic kidney disease (CKD), share common pathophysiologic origins, including hypertension, inflammation, hyperglycemia and increased renin-angiotensin-aldosterone system activity. Though the risk of HF & CVD is 2–8 times higher if patients have diabetes and CKD, it is also prevalent in people with other cardiometabolic conditions. Of note over half of heart failure patients have moderate to severe CKD. The CardioRenal Syndrome represents and heightens the relationship of these tightly related conditions. In recent cardiovascular outcomes trials (CVOTs), sodium glucose cotransporter 2 (SGLT2) inhibitors showed a Primary and Secondary prevention of HF and CKD, and identified the benefit of SGLT2i in advanced CKD and in HF with reduced function. This symposium will examine emerging approaches to preventing HF & CKD in Diabetes, and the management of HFrEF and advanced CKD in people with and without DM. The value of the cardiorenal syndrome concept will be examined

Learning Objectives

Upon completion of this symposium, participants should be able to:

- Describe the etiologic and pathophysiologic links between HF, CKD, and cardiometabolic disorders
- Explain the gaps in traditional HF management specifically in HF with reduced function- HFrEF and in the management of moderate to severe CKD
- Describe outcomes in trials with SGLT2 inhibitors involving patients with HFrEF and advanced CKD with and without type 2 diabetes and their impact on clinical practice
- Examine whether the cardiorenal syndrome represents more than its individual components and design relevant therapeutic regimens for the syndrome

Target Audience

This educational initiative is designed for cardiologists, endocrinologists, family physicians, internists, diabetologists, nurse practitioners, physician assistants, diabetes educators, and other healthcare professionals interested in the pathophysiology, prevention, and treatment of diabetes, obesity, cardiovascular disease, and associated conditions, as well as the effect of these conditions on health and society.

FACULTY 2020



Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE - Chair

Medical Director & Principal Investigator
The Metabolic Institute of America
Chair & Program Director, WCIRDC/HiD
Chair & Founder
International Committee for Insulin Resistance
Tarzana, California



Peter A. McCullough, MD, MPH, FACC FACP, FCCP, FAHA, FNKF, FCRSA

Vice Chief of Medicine
Baylor University Medical Center
Dallas, Texas



Maria Rosa Costanzo, MD, FAHA, FACC, FESC

Medical Director, Heart Failure Research,
Advocate Heart Institute
Medical Director, Edward Hospital Center for Advanced
Heart Failure
Naperville, Illinois, U.S.A



Katherine R. Tuttle, MD, FASN, FACP, FNKF

Executive Director for Research, Providence
Health Care Professor of Medicine, University
of Washington Co-Principal Investigator,
Institute of Translational Health Sciences



Mikhail N. Kosiborod MD, FACC, FAHA

Professor of Medicine
Saint Luke's Mid America Heart Institute
University of Missouri-Kansas City School of Medicine
Kansas City, Missouri



Muthiah Vaduganathan, MD, MPH

Cardiologist, Brigham and Women's Hospital,
Harvard Medical School
Boston, Massachusetts

CME Dinner Symposium

CME Supported Symposium is FREE ON-Demand for 90 DAYS following the meeting
Learn more: wcir.org/CMEsymposium

This CME Supported Symposium is included with the 18th WCIRDC Live Interactive
Online Registration. To register for the entire 18th WCIRDC FREE
Please visit: wcir.org/registration

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PESI Inc., and Metabolic Endocrine Education Foundation (MEEF). PESI Inc., is accredited by the ACCME to provide continuing medical education for physicians.

PESI Inc., designated this live educational activity for a maximum of **2 AMA PRA Category 1 Credit(s)**. Physicians should only claim credit commensurate with the extent of their participation in the activity.

For information please contact: info@tmioa.com or **818.342.1889**

This is a CME Program Supported by an Educational Grant from **AstraZeneca**